Table 1.
Characteristics of included patients.
| Clinical characteristics | Number of patients | p Response | p PFS | p OS |
|---|---|---|---|---|
| Total number | 28 | / | / | / |
| Sex, n (%)
Males Females |
19 (67.8%) 9 (32.2%) |
0.998 | 0.793 | 0.721 |
| Median age, years [range] | 68 [42-84] | 0.513 | 0.143 | 0.312 |
| ECOG(PS), n (%)
0 1 2 |
13 (46.4%) 12 (42.8%) 3 (10.8%) |
0.060 | 0.628 | 0.064 |
| Metastatic at diagnosis, n (%)
Yes No |
12 (42.8%) 16 (57.2%) |
0.123 | 0.195 | 0.593 |
| Sites of metastases, n (%)
Visceral Bone Nodes Brain |
21 (75.0%) 9 (32.2%) 3 (10.8%) 5 (17.8%) |
0.296 0.235 0.579 0.095 |
0.398 0.212 0.541 0.119 |
0.975 0.069 0.260 0.085 |
| Nr. of metastatic sites, n (%)
≤3 >3 |
18 (64.3%) 10 (35.7%) |
0.012 | 0.808 | 0.155 |
| Bajorin score, n (%)
0 1 2 |
12 (42.8%) 13 (46.4%) 3 (10.8%) |
0.071 | 0.539 | 0.321 |
| PD-L1 status, n (%)
Positive Negative Unknown |
7 (25.0%) 3 (10.8%) 18 (64.2%) |
0.658 | 0.262 | 0.175 |
| Location of primary tumor, n (%)
Bladder Upper tract |
27 (96.4%) 1 (3.6%) |
0.495 | 0.414 | 0.568 |
ECOG(PS), ECOG Performance Status; OS, overall survival; PFS, probability of progression-free survival.